While Cogent Biosciences Inc has overperformed by 2.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, COGT rose by 84.87%, with highs and lows ranging from $17.15 to $3.72, whereas the simple moving average jumped by 53.10% in the last 200 days.
On October 16, 2025, Stifel started tracking Cogent Biosciences Inc (NASDAQ: COGT) recommending Hold. A report published by Raymond James on September 03, 2025, Initiated its previous ‘Strong Buy’ rating for COGT. Scotiabank also rated COGT shares as ‘Sector Outperform’, setting a target price of $17 on the company’s shares in an initiating report dated March 07, 2025. Robert W. Baird February 26, 2024d its ‘Outperform’ rating to ‘Neutral’ for COGT, as published in its report on February 26, 2024. Citigroup’s report from February 08, 2024 suggests a price prediction of $11 for COGT shares, giving the stock a ‘Buy’ rating. Wedbush also rated the stock as ‘Neutral’.
Analysis of Cogent Biosciences Inc (COGT)
In order to gain a clear picture of Cogent Biosciences Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -95.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.19, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.95M can be a very valuable indicator of volatility for COGT stock. On a monthly basis, the volatility of the stock is set at 5.92%, whereas on a weekly basis, it is put at 7.28%, with a loss of -9.87% over the past seven days. Furthermore, long-term investors anticipate a median target price of $23.25, showing growth from the present price of $14.42, which can serve as yet another indication of whether COGT is worth investing in or should be passed over.
How Do You Analyze Cogent Biosciences Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 19.43%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 88.14% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
